相关实验视频

Updated: Jan 8, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

在EGFR-TKI抗性NSCLC中,抗体药物结合剂的效果优于化疗:贝叶斯网络元分析

Yueying Chen¹, Yanjun Du², Juan Ni¹

¹Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Therapeutic advances in medical oncology

|December 19, 2025

概括

萨西图苏巴 Tirumotecan (Sac-TMT) 和dato-DXd 显示出对耐受EGFR-TKI的非小细胞肺癌 (NSCLC) 患者的优越疗效. 与化疗相比,这些新型药物提供了更好的生存结果.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

针对性疗法已经为具有特定基因组变异的患者提供了先进的非小细胞肺癌 (NSCLC) 治疗.
在NSCLC中管理EGFR-TKI耐药性仍然是一个重大的临床挑战.
确定EGFR-TKI进展后的最佳治疗策略至关重要.

研究的目的:

进行对现有治疗方案的疗效和安全性进行比较评估,以治疗晚期NSCLC.
确定EGFR-TKI治疗后患有疾病进展的患者的最佳治疗策略.
为了确定EGFR-TKI抗性NSCLC的优质治疗选择.

主要方法:

随机对照试验 (RCT) 的系统审查和贝叶斯网络元分析.
搜索了主要的数据库 (PubMed,Embase,Cochrane,科学网,临床试验.gov) 和会议记录.
在累积排名曲线 (SUCRA) 下使用的表面来排名治疗疗效.

主要成果:

萨西图苏巴 Tirumotecan (Sac-TMT) 显著改善了无进展生存 (PFS) 和整体生存 (OS) 与化疗相比 (SUCRA:PFS的0.997,OS的0.946).
在免疫检查点抑制剂和两种特异性抗体 (p < 0.05) 上,Sac-TMT显示了优越的PFS益处.
达托帕马布德鲁克斯泰干 (Dato-DXd) 和双特异性抗体疗法也显示出有希望的疗效;三重疗法具有更高的严重不良事件.

结论:

萨西图苏巴 Tirumotecan (Sac-TMT) 和达托塔巴 Deruxtecan (Dato-DXd) 是高级NSCLC后EGFR-TKI进展的高度有效的选择.
基于双特定抗体的疗法也在可控毒性方面是有效的.
像Sac-TMT和Dato-DXd这样的创新药物代表了治疗耐火性NSCLC种群的关键进展.

关键词:

抗体与药物结合物的结合物.两种特异性抗体的抗体皮质生长因子受体氨酸激酶抑制剂免疫疗法免疫疗法网络元分析网络元分析非小细胞肺癌的肺癌.

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...